
INDEX

Note: Page entries in *italics* refer to figures/photos; tables are noted with a t.

- major characteristics of, 5
- Adaptive immune system, major properties of, 2t
- Adaptive immunity, 2–3, 9
 - cells and organs involved in, 26–31
 - comparison of specificity and cellular distribution of receptors used in, 16
 - relationship with innate immunity, 33, 33
- Adaptive T-regulatory cells, 200
- Adaptiveness, in adaptive immune response, 5
- Adaptor, 112
- Adaptor molecules, 158
- Adaptor proteins, 17
- Additive effects, 177
- Address code, 112

- Affinity chromatography, 336
 Affinity maturation, 29, 63, 96, 107
 Age-related macular degeneration, 222, 230
 Agglutinating antibodies, IgM molecules as, 60
 Agglutination, 56, 67
 passive, 71
 Agglutination inhibition, 71
 Agglutination reactions, 70–72
 applications of, 71–72
 Aggregated IgG, 56. *See also* Immunoglobulin G (IgG)
 Agonists, 207
 AIDS-associated diseases, defined by the CDC, 285, 285t.
 See also Acquired immunodeficiency syndrome (AIDS)
 Air filters, 242
 AIRE gene product, 196. *See also* Autoimmune regulator (AIRE) gene
 role in negative selection, 148
 Airway inflammation, 241
 Alkaline phosphatase, 280
 Alleles, 93, 120
 Allelic exclusion, 93, 97, 102
 Allelic forms, 54
 Allergens, sensitization to, 234
 Allergic dermatitis, 241
 Allergic reactions, 9, 233, 245
 activation phase of, 235–237
 clinical aspects of, 240–242
 clinical tests and clinical intervention for, 242
 effector phase of, 237–240
 general characteristics of, 234
 sensitization phase of, 234–235
 therapeutic agents used to treat, 241
 Allergic rhinitis, 240, 245
 Allergies, 233
 clinical tests and clinical intervention for, 242–244
 pharmacologic agents used in treating, 243t
 treatment of, 191
 Alloantigen recognition, by T cells, 301–302
 Allogeneic HCT, 307, 308. *See also* Hematopoietic stem cell transplantation (HCT)
 Allogeneic transplant, 299
 Allograft rejection, 264, 309
 categories of, 300–301
 fetus and, 309
 immune mechanisms responsible for, 300
 role of MHC molecules in, 301–302
 role of T-cell lineages and cytokines in, 302–303
 Allograft survival, prolongation of, 304–307, 309
 Allografts, 299
 Allotypes, 55, 64
 Ig, 54
 Alpha-1-acid glycoprotein (AGP), 22t
 Alpha 1-antitrypsin, 22t
 Alpha 2-macroglobulin, 22t
 Alpha 2-antichymotrypsin, 22t
 α -fetoprotein (AFP), 309, 313
 detection of, 321
 $\alpha\beta$ T cells, characteristics of, 148
 $\alpha\beta$ TCR, 137, 138. *See also* T-cell receptors (TCRs)
 Ig compared with, 138, 139t
 structure of, 138
 V and C regions and antigen-binding site, 137, 138
 $\alpha\beta\gamma\delta$ CD3+CD4+CD8+ thymocyte, 146
 $\alpha\beta\gamma$ integrin, 142
 Alternative activation pathway, 18, 18
 Alternative complement activation pathway, 217, 218, 220, 220–221, 230
 Alternative pathway C3 convertase, 221
 Alternative splicing, 93
 Aluminum hydroxide, 42
 Aluminum phosphate, 42
 Alveolar macrophages, 13
 Am allotype marker group, 54
 Amino acid sequences, of globular domains, 51
 Aminopeptidases, 126
 Amplification loop, 218
 Amyloid, 291
 Anamnestic response, 5, 38, 62, 339
 Anaphylactic response, 225
 Anaphylotoxins, 218, 230, 236
 production of, 225, 226
 Anaphylaxis, 163, 233, 240, 246
 systemic, 238
 Anchor residues, 122
 Anemia, 205
 Anergy, 196, 196–197, 198, 213
 Angioedema, hereditary, 280–281
 Animal models, experimental, 81–82
 Antagonistic effects, 177
 Antagonists
 autoantibodies acting as, 206
 cytokine, 189–190
 Anthrax vaccine, 338
 Anti-HEL transgenic models, 197
 Anti-ICAM-1, 306
 Anti-idiotype antibodies, 54, 54
 Anti-idiotypic sera, 54
 Anti-immunoglobulin test, 70, 71
 Anti-inflammatory agents, 305
 Anti-neutrophil cytoplasmic antigen (ANCA)-associated vasculitis, 206t, 209
 Anti-PD-1 antibody therapy, 323
 Anti-RBC autoantibody, 252
 Anti-RNA-specific B cells, 205
 Anti-thymocite globulin (ATG), 306
 Antibacterial defenses, 331
 Antibodies, 47, 331
 biologic activities of, 47–48
 humanized, 80
 neutralizing, 331

- polyspecific, 110
preformed, 300
structure and function of, 47–64
- Antibody-binding proteins, expression of, 336
- Antibody-deficiency syndrome, 73
- Antibody-dependent, cell-mediated cytotoxicity (ADCC), 58, 79, 206, 249–250, 250, 331, 333
- Antibody diversity, generation of, 95–96
- Antibody-drug conjugates, 323, 325
- Antibody feedback, 114, 114
- Antibody-mediated cellular dysfunction, 250–251
- Antibody-mediated immunity, 269
- Antibody-mediated injury, mechanisms of, 250
- Antibody-mediated rejection, 300
- Antibody molecule, typical, 6
- Antibody production assays, 78–79
- Antibody response kinetics, following immunization, 62–63
- Antibody responses
- kinetics of, 59
 - primary, 62
 - secondary, 62–63
 - thymus-dependent, 104
- Antibody specificity, diversity in, 97
- Antibody structure, genetic basis of, 88–98
- Antibody synthesis
- in mucosal tissue, 107–109
 - sites of, 105–110
- Antibody therapies, indications for, 324t–325t
- Anticytokine therapies, 212, 214
- Antigen, 35
- Antigen-antibody complexes, 107, 217, 219
- Antigen-antibody interactions, 67–74, 69
- forces involved in, 52, 67
 - primary, 68–70
 - secondary, 70–74
- Antigen-binding fragment (Fab), 48. *See also* Fab entries
- Antigen-binding molecules, 111
- Antigen-binding sites, 6
- Antigen binding sites, 38–39
- Antigen molecules, cross-linking, 67–68
- Antigen presentation, 13, 14
- MHC role in, 118, 118–119
- Antigen-presenting cells (APCs), 3, 5, 13, 26, 31–32, 119, 153, 181, 301
- Antigen-specific antibodies, binding of antigens to, 41
- Antigen-specific B cells, 20
- Antigen-specific IgG, 55. *See also* Immunoglobulin G (IgG)
- Antigen-specific lymphocytes, 26
- Antigen-specific naïve lymphocytes, frequency of, 32–33
- Antigen-specific T-cell receptor, 137–143
- Antigenic determinants, 36, 42, 44
- Antigenic drift, 335
- Antigenic epitopes, 39
- Antigenic shift, 335
- Antigenic variation, 335
- Antigenicity, 44
- antigen-binding site and, 38–39
- Antigens, 3
- binding to antigenic-specific antibodies or T cell receptors, 41
 - dosage and administration route of, 37–38
 - endogenous, 126, 126–127, 252
 - enhancing B-cell responses to, 225, 226, 230
 - exogenous, 124, 125, 126, 252
 - fate after penetration, 31, 31–32
 - heterophile, 42
 - histocompatibility, 301
 - major classes of, 40–41
 - molecule interactions with, 137–139
 - oncofetal, 313
 - T-cell dependent, 27
 - thymus-dependent, 165, 198
 - thymus-independent, 105
 - transplantation, 301
 - tumor, 312–315
 - unresponsiveness to, 129
- Antihistamines, 243t, 246
- Antinuclear antibodies (ANAs), 208
- Antitoxins, 334
- Antiviral activity, of IgA, 61
- Antiviral therapy, 286
- AP-1 transcription factor, 158
- Apoptosis, 14, 15, 102, 170, 173, 195
- Arachidonic acid, 238
- Arthus reaction, 255, 256, 256
- Arylsulfatase, 238
- Ascaris antigen, IgE and, 62
- Aspergillus fumigatus*, 163
- Association constant, 68–70
- Asthma, 163, 189, 233, 238, 241–242, 246
- treatment of, 191, 241
- Ataxia, 210
- Ataxia telangiectasia (AT), 271t, 274
- Atopic dermatitis, 241, 245
- Atopic individuals, 234
- Atopic urticaria, 241
- Atopy, 234
- Atypical hemolytic-uremic syndrome, 228
- Atypical Hodgkin's lymphoma, 285
- Augraft, 299
- Autoantibodies, 252
- marker, 208
- Autoantigens, 194
- Autocrine property, 177, 178
- Autograft, 298
- Autoimmune diseases, 214
- environmental susceptibility to, 203–205
 - genetic susceptibility to, 202–203
- HLA association, allele, and strength of association, 203
- initiation of, 202, 214

- Autoimmune diseases (*continued*)
 organ-damage-mediating antibodies and, 205–209
 T cell organ damage and, 210–213
 target autoantigens and major effector pathway in, 206t
 therapeutic strategies for, 212–213, 214
- Autoimmune hemolytic anemia, 205–206, 206t
- Autoimmune lymphoproliferative syndrome (ALPS), 200, 276
- Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), 196
- Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, 148, 275
- Autoimmune regulator (AIRE) gene, 148. *See also* AIRE gene product, 196, 275
- Autoimmunity, 9, 36, 189, 192
 disease and, 201–205
 drug and hormonal triggers of, 205
 mechanisms for triggering of, 204, 204
- Autoinflammatory conditions, 163
- Autologous graft, 299
- Autologous HCT, 307. *See also* Hematopoietic stem cell transplantation (HCT)
- Autophagy, 127
- Autoreactive B cells, 204
- Autoreactive lymphocytes, 195
- Autosomal recessive SCID, 271–272. *See also* Severe combined immunodeficiency diseases (SCID)
- Avidity, 70, 197
- Azathioprine, 305
- Azidothymidine (AZT), 286
- B-1 cells, 109–110
- B7 family, 141
- B7.1 molecule, 156
- B7.2 molecule, 156
- B7 molecules, 156
- B7-CD28 costimulator interactions, 158
- B7-CD152 costimulator interactions, 158
- B-cell-associated immunodeficiency disorders, 276–277
- B-cell co-receptor, 111
- B-cell differentiation, early, sites of, 101
- B-cell hybridomas, 80
- B-cell linker protein (BLNK), 112
- B-cell lymphoblastic leukemia/lymphoma (B-ALLs), 288
- B-cell malignancies, correlation of B-cell development with, 289
- B-cell-mediated immunity, 269
- B-cell membrane proteins, 110–114
- B-cell neoplasms, 287, 288–291, 289
- B-cell proliferation assays, 78
- B-cell receptors (BCRs), 3, 6, 8, 26, 35, 47, 64, 102, 137, 194. *See also* BCR entries
- B-cell responses, 5
- B-cell signaling
 enhancement of, 113
 negative regulation of, 113–114
- B-cell superantigens, 335
- B cells, 3, 6. *See also* B lymphocytes; Bursa-derived cells (B cells)
 activation by antigens, 112–113, 113
 activation of, 111, 115
 adaptive immune responses and, 26
 anergic, 196–197
 antibody production by, 78–79
 antigen-specific, 20
 autoreactive, 204
 clonal selection theory of, 4
 cognate, 105
 epitopes recognized by, 39, 39t
 help for in response to TD antigens, 165–166, 166
 immature, 103–104
 intracellular signaling in, 112–114
 marginal-zone, 104, 109
 mature, 104
 mechanisms of central tolerance in, 195–197, 196
 molecules expressed at surface of, 110
 responses to antigens, 225
 responses to tumors, 317
 transitional, 104
- B-lymphocyte deficiency, 269t
- B-lymphocyte stimulator (BLyS), 104
- B lymphocytes, 35, 38, 268. *See also* B cell entries
 antigen receptors expressed as transmembrane molecules on, 7
 biology of, 100–115
 development of, 100–105
 differentiation of, 100–101, 101
 repertoire of, 96
- Bacille Calmette-Guerin (BCG), 43
- Bacillus anthracis*, 36
- Bacteria
 encapsulated, 334
 extracellular, 163
 immobilization of, 58
 immunity to, 331–332
 pyogenic, 228
- Bacterial septic shock, 188, 192
- Bacterial toxins, 334
- Bactericidal activity, IgA role in, 61
- Bacterium-carrier vaccines, 343
- BAFF, 104
- BAFF/Blys (belimumab), 213
- Bare lymphocyte syndrome (BLS), 131, 271t, 272–273, 273
- Basiliximab, 306
- Basophils, 12, 13, 233, 234, 235, 238, 245
- BCG, 323, 325
- bcl-1* gene, 289
- bcl-2* gene, 288, 290
- bcl-6* gene, 291
- Bcl-6 transcription factor, 107, 165, 166
- BCR editing, 103. *See also* B-cell receptors (BCRs)

BCR signaling, 102
Belatacept, 307
Bence Jones proteins, 48, 321
 β_2 microglobulin, 120
Binding affinities, 52
Biotechnology, 325
Bispecific antibody, 323
Blister formation, 262
Blocking antibody, 242
Bloom syndrome, 274
Bone marrow, 27, 27, 101
Bordetella pertussis, 43
Borrelia burgdorferi, 163, 290
Botulinus, 58
Brain, immune privilege of, 201
Brambell receptor, 55
Bronchodilators, 242, 243t, 246
Bronchus-associated lymphoid tissue (BALT), 29
Bruton's agammaglobulinemia, 73, 276
Bruton's tyrosine kinase (Btk), 102–103
B molecules, 112
Burkitt's lymphoma, 285, 315
Burkitt's lymphoma/leukemia, 288, 289
Burnet, Frank MacFarlane, 195
Bursa-derived cells (B cells), 100. *See also* B cell entries; B lymphocytes
Bursa of Fabricius, 100

c-abl oncogene, 315t
C gene, 90
c-H-ras oncogene, 315t
c-K-ras oncogene, 315t
c-myc oncogene, 288, 315t
C-reactive protein (CRP), 20, 21, 22t, 180, 181, 191, 226
C-type lectin receptors (CLRs), 16, 17
C3 cleavage, 217, 219, 220–221, 221, 230
C5 cleavage, 218, 221
C5 convertases, 222
C1 deficiency, 228, 229t, 280
C2 deficiency, 228, 229t, 280
C3 deficiency, 228, 229t
C4 deficiency, 228, 229t, 280
C1 esterase inhibitor (C1INH), 222
C1 esterase inhibitor deficiency, 280
C3 nephritic factor, 229
C5a, 218, 252, 253, 256
C3a opsonin, 217, 230, 252, 253, 256
C3a receptor, 224t
C5a receptor, 224t
C5b, 218
C4b-binding protein (C4BP), 223
C3b opsonin, 217, 218, 220, 221, 230
C3c opsonin, 223
C3d opsonin, 223
C3dg opsonin, 225

Cachexia, 286
Calcineurin, 113, 158
Campylobacter jejuni, 289
Cancer-antigen 125, 321
Cancer immunity, effector mechanisms in, 317t
Cancer(s), 189
activation of cellular proto-oncogenes in, 315t
immunoediting phases of, 316, 317
immunologic factors influencing incidence of, 315–316
immunotherapeutic strategies in, 323, 325
treatment of, 190–191
Candida albicans, 163, 333, 334
Candidiasis, 275
Carbohydrates, as antigens, 40
Carcinoembryonic antigen (CEA), 313, 321
Carcinogens, 313
Carrier, 35
Carrier protein, 129, 167, 168
Caspase-1, 17
CCR5 chemokine receptor, 184, 282, 283
CCR7 chemokine receptor, 142, 155
CCR10 chemokine receptor, 159
CD10, 101
CD55, 89
CD58, 89
CD1, lipids and glycolipids presented by, 130
CD1 antigen, 378t
CD2 antigen, 378t
CD3 antigen, 378t
CD4 antigen, 378t
CD5 antigen, 378t
CD8 antigen, 378t
CD18 antigen, 378t
CD19 antigen, 378t
CD20 antigen, 378t
CD21 antigen, 378t
CD25 antigen, 378t
CD28 antigen, 378t
CD32 antigen, 379t
CD34 antigen, 379t
CD40 antigen, 379t
CD44 antigen, 379t
CD50 antigen, 379t
CD54 antigen, 379t
CD55 antigen, 379t
CD58 antigen, 379t
CD74 antigen, 379t
CD80 antigen, 379t
CD81 antigen, 379t
CD86 antigen, 379t
CD95 antigen, 379t
CD97 antigen, 379t
CD102 antigen, 379t
CD152 antigen, 379t
CD154 antigen, 379t

- CD178 antigen, 379t
 CD210 antigen, 379t
 CD212 antigen, 380t
 CD213 antigen, 380t
 CD217 antigen, 380t
 CD220 antigen, 380t
 CD225 antigen, 380t
 CD230 antigen, 380t
 CD247 antigen, 380t
 CD281 antigen, 380t
 CD282 antigen, 380t
 CD283 antigen, 380t
 CD284 antigen, 380t
 CD288 antigen, 380t
 CD289 antigen, 380t
 CD8 binding, to MHC class I molecule invariant region, 122
 CD40-CD40L interaction, 278
 CD3 chains, mutations in, 275
 CD4 coreceptor, interaction with MHC class II molecules, 156
 CD154 ligand, 141
 CD40 ligand (CD40L), 141, 156, 198, 306
 CD markers, 100
 CD1 molecule, 129
 CD2 molecule, 141, 156
 CD3 molecule, 139, 140
 CD4 molecule, 140, 141
 HIV-1 binds to, 141
 CD8 molecule, 140, 141
 CD16 molecule, 250
 CD19 molecule, 101, 111, 111, 115
 CD20 molecule, 103
 CD21 molecule, 111, 111, 115
 CD22 molecule, 113
 CD25 molecule, 7
 CD28 molecule, 141, 156
 CD32 molecule, 114
 CD35 molecule, 223
 CD40 molecule, 112
 CD50 molecule, 156
 CD54 molecule, 156
 CD58 molecule, 156
 CD74 molecule, 124
 CD80 molecule, 156
 CD81 molecule, 111, 111, 115
 CD95 molecule, 200
 CD152 molecule, 141, 156, 159
 CD154 molecule, 141, 156
 CD225 molecule, 111, 111, 115, 141
 CD247 molecule, 139
 CD273 molecule, 160
 CD274 molecule, 160
 CD279 molecule, 159
 CD19 molecules, 141
 CD21 molecules, 141
 CD81 molecules, 141
 CD46 opsonin, 223
 CD55 opsonin, 223
 CD59 opsonin, 224
 CD59 protein, 224
 CD4+ T-cell clone, proliferation of, 158, 159
 CD4+ T-cell subsets, cross-inhibition of, 164–165, 164t
 CD4+ T cells, 79, 119, 140, 199, 331
 activation of, 155, 155–160, 172
 alternative activation of, 160
 cytokine-producing, major subsets of, 161–164
 function of, 160–168, 161
 further differentiation of, outside the thymus, 149
 intracellular events in activation of, 156–159, 157
 paired interactions at surface of, 155–156
 CD8+ T cells, 119, 140, 162
 activation and function of, 168–169, 172
 activation by viruses, 168–169, 169
 cytotoxic, 331
 further differentiation of, outside the thymus, 149
 MHC restriction killer function and, 170–171
 target cell killing by, 169–171, 170
 CD11a antigen, 378t
 CD79a/CD79b antigens, 379t
 CD11aCD18 molecule, 141, 156
 CD179b, 102
 CD4:CD8 T-cell ratio, in HIV, 284
 CD62L antigen, 379t
 CD62L molecule, 142
 cDNAs, 83, 84. *See also* Deoxyribonucleic acid (cDNA) clones
 CDR1, 51, 52, 138. *See also* Complementarity-determining regions (CDRs)
 CDR2, 51, 52, 138
 CDR3, 51, 53, 138
 Cell-cell hybridization, 48
 Cell culture, 79–81
 Cell-mediated immunity, 7–8, 82, 162, 269, 332
 immunodeficiency disorders associated with, 274–276
 Cell-mediated responses, 26
 Cell membrane determinants, reactions involving, 252
 Cell membrane receptors, reactions involving, 252
 Cell sorting, 76
 Cell-surface adhesion molecules (CAMs), 29
 Cell-surface receptors, 250
 Cellular assays, 78–79
 Cellular deficiencies, reversing, 190
 Cellular dysfunction, antibody-mediated, 250–251
 Cellular gene products
 mutant, 314–315, 314t
 normal, 313–314, 314t
 Cellular immunity, 26
 Cellular-mediated immunity, 331
 Centers for Disease Control and Prevention (CDC), 285, 308
 Central memory cells, 171
 Central tolerance, 103, 147, 194, 195, 195, 195–197, 196, 213
 Ceruloplasmin, 22t

Cervical cancer vaccine, 337
Chaperone, 124
Chédiak-Higashi syndrome (CHS), 279, 279
Chemical complexity, as requirement for immunogenicity, 36
Chemokine receptors, 112, 185, 186
Chemokines, 177, 183
Chemotactic cytokines, 21, 177
Chemotactic factors, 238
Chemotaxis, 178, 179, 183
Chimeric antibodies, 306
Chimeric antigen receptor therapy (CAR therapy), 323
Chlorambucil, 305
Cholera, 334
Chromosomal translocation, 315
Chronic granulomatous disease (CGD), 279, 279–280
Chronic inflammation, 23
Chronic latent phase, of HIV, 284
Chronic lymphocytic leukemia (CLL), 290
Chronic mucocutaneous candidiasis, 275
Chronic myelogenous leukemia (CML), 314
Chronic rejection, 301
Class, 48
Class I cytokine receptors, 185, 186
Class I region, 130
Class II cytokine receptors, 185, 186
Class II region, 130
Class switch recombination, 94, 94–95, 107
Class switching, 62, 139
 immunoglobulin, 27
Classical activation pathway, 18, 18
Classical complement activation pathway, 217, 218,
 218–219, 220, 230
Classical pathway C3 convertase, 219, 220
Clonal amplification, 312
Clonal ignorance, 197
Clonal selection theory, 3–5, 4, 195
Clonally distributed receptor, 137
Cloned lymphoid cell lines, 79–80
Clonotypic proteins, 313
Clotting, 21, 48
Clusterin, 224
Clusters of differentiation (CD) antigens, 77
C11NH deficiency, 229
Co-receptors, 140, 140–141
Co-stimulation blockers, 307
Co-stimulator function, 129
Co-stimulator interactions, 141
Co-stimulator molecules, 111–112
Co-stimulator pairs, 153, 154, 156
 in T_{FH} cell-dependent antibody synthesis and isotype
 switch, 166–167
Co-stimulators, 7
Co-stimulatory ligands, 141
Coagulation pathway, 21
Coagulation system, 21

Codominant expression, 131
Cofactors, 223
Cognate (cell-to-cell) interaction, 181
Cognate T and B cells, 105
Cohn fractionation, 346
Cold agglutinins, 206, 252
Cold-induced urticaria, 236
Colonization, host-microbe interaction and, 329, 329, 330
Colony-stimulating factors (CSFs), 184, 347
Colostrum
 immunoglobulin levels in, 344t
 passive immunization via, 344
Commensalism, host-microbe interaction and, 329, 329, 330
Common lymphoid progenitor (CLP) cells, 144
Common mucosal immune system, 108
Common variable immunodeficiency disease (CVID), 277
Common γ chain, 186, 187, 192
Complement, 217–230, 268, 331, 333
 activation of, 58, 67, 217–222, 218, 230
 biologic activities of, 224–228
Complement activation pathways, 18, 18
Complement activity, regulation of, 222–224
Complement cascade, 18
 proteins in, 19t
Complement components
 defective control of, 280–281
 deficiencies in, 269t
 early, 280, 281
 late, 280, 281
Complement deficiencies, 228–230, 229t, 230, 255
Complement-dependent cytotoxicity (CDC) cross-match tests,
 303
Complement factors, 22t
Complement fixation, of IgM, 59
Complement-mediated opsonization, 47
Complement-mediated reactions, 249
Complement receptor (CR) 1 (CD35), 223. *See also CR*
 entries
Complement receptors, cell distribution and function of, 224t
Complement specific antibody, 332
Complement system, 6, 11, 18, 230, 332
Complement system abnormalities, diseases caused
 by, 280–281
Complementarity-determining regions (CDRs), 38, 47, 51,
 52, 64, 92, 139. *See also CDR* entries
Complete Freund's adjuvant (CFA), 43
Complex, 118
 genes linked in, 130, 131
Computer-assisted tomography (CAT), 321
Concanavalin A (Con A), 78, 160
Conformational epitopes, 39
Congenital thymic aplasia, 274–275
Congenitally athymic (nude) mice, 82
Conjugate vaccines, 109, 167–168, 168, 173
Conjugated polysaccharide vaccines, 342–343

Constant region, of immunoglobulins, 50, 51
 Constitutive expression, 119
 Contact dermatitis, 261
 Contact hypersensitivity, 259, 265
 Contact sensitivity, 261–262, 262
 Continuous T-cell epitopes, 39
 Coombs-Gell hypersensitivity designations, 233–234
 Coombs test, 70, 71, 206
 Coordinate regulation, 131
 Coreceptor molecules, 140
 Cortex, 28, 28–29, 144, 145
 Corticosteroids (CSTs), 212, 214, 241, 243t, 246, 265, 305
Corynebacterium parvum, 43
 Cough reflex, 11
 Cowpox, 337
 CR3 deficiency, 228, 229t
 CR1 molecule, 225, 228. *See also* Complement receptor (CR) 1 (CD35)
 CR2 molecule, 225, 228
 CR3 molecule, 225
 CR1 receptor, 224, 224t
 CR2 receptor, 224t
 CR3 receptor, 224, 224t
 CR4 receptor, 224, 224t
 CRIg receptor, 224, 224t
 Crisis phase, of HIV, 284–286
 Crohn's disease, 213
 Cromolyn sodium, 243t, 246
 Cross-inhibition, of CD4+ T-cell subsets, 164–165, 164t
 Cross-linking, of antigen molecules, 67–68
 Cross-match test, 303–304
 Cross-presentation, 127, 127–128
 Cross-reacting idiotypes, 55
 Cross-reactivity, 41–42, 44, 313
Cryptococcus neoformans, 333, 334
 C1s esterase, 219
 C3dg, 111
 CTLA-4, 307
 CTLA-4Ig, 213
 CTLA-4 molecule, 141, 159, 160, 199
 Cutaneous basophil hypersensitivity, 264
 Cutaneous inflammatory reactions, 263
 Cutaneous lymphocyte antigen (CLA), 159
 Cutaneous T-cell lymphoma, 292
 CXCR4 chemokine receptor, 184
 CXCR5 chemokine receptor, 165
 Cyclic adenosine monophosphate (cAMP), 236
 Cyclic guanosine monophosphate (cGMP), 236
 Cyclin-dependent kinase-4 (CDK-4), 314
 Cyclophosphamide, 305
 Cyclosporin A, 158, 212
 Cyclosporine, 306
 Cytokine-activated killer cells, destruction of tumor cells by, 318
 Cytokine cascade, 179

Cytokine inhibitors/antagonists, 189–190
 Cytokine receptor chains, 186
 Cytokine receptor families, 185–186
 Cytokine receptor-mediated signal transduction, 186–188
 Cytokine-receptor-specific antibodies, 191
 Cytokine receptors, 185–188, 186, 191
 role in disease, 188–189
 therapeutic exploitation of, 189–191
 Cytokine synthesis
 by CD4+ T cells
 cross-inhibition of CD4+ T-cell subsets, 164–165
 further points on, 165
 major subsets of cytokine-producing CD4+ T cells, 161–164
 other sets of cytokine-producing CD4+ T cells, 165
 overview of, 161
 Cytokines, 4, 7, 21, 176–192
 adaptive immune response regulation by, 181
 agents that interfere with, 306
 common cell sources and cascading events associated with, 170
 common functional properties of, 177–178
 common systemic activities of, 178–179
 in delayed-type hypersensitivity reaction, 261t
 differentiation-inducing, 181–182
 with endogenous pyrogenic properties, 23
 functional categories of, 179–185, 180t, 191
 general properties of, 177–179
 hematopoiesis-stimulating, 184–185
 history of, 176–177
 IL-17 family of, 182, 182t
 in inflammatory response, 183
 innate immune response facilitation by, 179–181
 leukocyte movement and, 183–184
 lineage-specific T-cell differentiation inhibition by, 182
 pleiotropic and redundant properties of, 177, 191
 proinflammatory, 163
 receptors for, 112
 role in allograft rejection, 302–303
 role in disease, 188–189
 signature, 161
 in T_{FH} cell-dependent antibody synthesis and class switching, 166–167
 therapeutic exploitation of, 189–191
 tumor cells and growth-promoting effect of, 319
 Cytomegalovirus (CMV), 228
 Cytomegalovirus human immune globulin (CMV-IVIG), 346
 Cytosolic enzymes, 126
 Cytotoxic CD8+ T cells, 331
 Cytotoxic drugs, 305–306
 Cytotoxic effects, of T cell subsets, 7
 Cytotoxic T cells (T_C cells), 7, 153
 Cytotoxic T lymphocytes (CTLs), 168, 284, 315
 Cytotoxicity, antibody-dependent, cell-mediated, 249–250, 250
 Cytotoxicity assay, 79

- Daclizumab, 306
Damage-response framework, 328, 329
Dark zone, 106, 107
Dead cells, removing, 225–226, 227, 230
Decay-accelerating factor (DAF), 89, 223
Declining phase, in primary response, 62
Degradability, as requirement for immunogenicity, 36
Delayed-type hypersensitivity (DTH), 162, 234, 259–265, 332
 characteristics and pathophysiology of, 259–261
 cytokines involved in, 261t
 examples of, 261–264
 mechanisms involved in, 260–261
 sensitization and elicitation stage in, 260
 treatment of, 264–265
Deletion, 103, 195
Dementia, AIDS-associated, 286
Dendritic cells (DCs), 5, 14, 26, 43, 129, 268, 323
 follicular, 107
 immature, 154–155
 as key APCs for naïve T cells, 153–155
 maturation in response to pathogen, 154
 mature, 155
 myeloid, 154
 plasmacytoid, 154
 thymic, 144
Deoxyribonucleic acid (cDNA) clones, 2. *See also* cDNAs;
 DNA entries; Recombinant DNA entries
Dermatographic urticaria, 236
Desensitization, 242
Developmental checkpoints, 101
Diabetes mellitus, Type I, 206t, 211
Diacylglycerol (DAG), 113, 158
Diffuse large B-cell lymphoma, 290–291
DiGeorge syndrome, 6, 144, 274–275, 300
Dimeric IgA, 60, 61
Diphtheria, 334
Diphtheria antitoxin, 335t
Diphtheria toxoid, 342
Direct agglutination, 71
Direct-binding immunoassays, 74–76
Direct Coombs test, 71
Direct immunofluorescence, 76
Direct mechanism, of T-cell alloantigen recognition, 301,
 302, 309
Discontinuous epitopes, 39
Discrimination between self and nonself, 5, 100
Disease, 329, 329
 autoimmunity and, 201–205
 role of cytokines and cytokine receptors in, 188–189
Disulfide bonds, intrachain, 51
Diversity, 100
Diversity (D) segment, 92
DNA precursor, 304. *See also* Deoxyribonucleic acid
 (cDNA) clones; Double-stranded DNA (dsDNA)
DNA vaccines, 9, 322, 343
Domains, 51
Donor-specific antibody (DSA), 300
Double-diffusion test, 73
Double-negative (DN) cells, 145–146
Double-positive (DP) cells, 146, 147, 150
Double-stranded DNA (dsDNA), 197, 208. *See also*
 Deoxyribonucleic acid (cDNA) clones
Drosophila melanogaster embryos, toll-like receptors and
 dorsal-ventral patterning in, 16
Drug-induced reactions, 251
Drug triggers, of autoimmunity, 205
Drugs, immunosuppressive, 305, 305t
DTP vaccine, 339
Duffy blood-group antigen, 186
Duncan syndrome, 278
Dysarthria, 210
Dysphagia, 210
E-selectin, 23
Early complement components, deficiencies of, 280, 281
Early region genes, 315
EBV-associated lymphomas, 285. *See also* Epstein Barr virus
 (EBV)
EBV infections, 287
Eczema, 262, 265
Edema, 20, 236, 242
Educated T cells, positive selection and, 146, 149
Effector CD8+ T cells, generation of, 168–169
Effector cell assays, 79
Effector cells, 26, 142, 153
Effector mechanisms, in tumor immunity, 316–318, 317t
Effector memory cells, 171
Effector phase, of allergic reactions, 234, 237–240
Effector site, 108
Effector T cells, 149, 159
Efferent lymphatic vessels, 29
Ehrlich, Paul, 3, 201
Electrophoresis, 48, 48
Electrostatic forces, 68, 84
Electrostatic interactions, 41
Elicitation stage, in delayed-type hypersensitivity, 260, 260
Elimination, host-microbe interaction and, 329, 329
Elimination phase, of cancer immunoediting, 316, 317
Encapsulated bacteria, 334
Endocrine property, 177, 178
Endocytosis, 19
Endogenous antigens, 252
Endogenous pyrogens, 23, 179
Endogenous antigens, 126, 126–127
Endosomes, 19
Endothelial cell adhesion molecules (ECAMs), 21
Endothelium, leukocyte tethering, rolling, and adhesion to, 23
Endotoxins, 332
Enterotoxins, 188
Environmental intervention, against allergies, 242

- Enzyme-linked immunosorbent assay (ELISA), 75, 76, 78, 85, 242, 286
- Enzyme-linked immunosorbent spot test (ELISPOT), 264
- Enzyme-linked immunospot assay, 79
- Enzymes, extracellular, 336
- Eosinophilic cationic protein (ECP), 240
- Eosinophilic chemotactic factors (ECFs), 238
- Eosinophils, 12, 13, 238, 333
- Epitopes, 6, 36, 37, 40, 44, 47, 52, 68
immunodominant, 124
internal image of, 54
recognition by B cells and T cells, 39, 39t
shared, 212
single and multiple, antigenic structures containing, 41
- Epstein-Barr virus (EBV), 79, 209, 228, 278, 336. *See also* EBV entries
- Equilibrium dialysis, 68
- Equilibrium phase, of cancer immunoediting, 316, 317
- Equivalence zone, 72
- Erythema, 242, 262, 263, 263, 264, 265
- Erythroblastosis fetalis, 251
- Erythrocyte sedimentation rate (ESR), 21
- Erythrocytes, 14
- Escape phase, of cancer immunoediting, 316, 317
- Escherichia coli*, 42
- Exogenous antigens, 124, 125, 126, 252
presented in MHC class I pathway, 127–128
- Exons, 88
- Exonucleases, 95
- Experimental animal models, 81–82
- Experimental autoimmune encephalomyelitis (EAE), 210, 211
- Exponential phase, in primary response, 62
- Extracellular bacteria, 163
- Extracellular bacterial pathogens, 332
- Extracellular enzymes, 336
- Extravasation, 22, 29
- Extrinsic allergic alveolitis, 256
- Eye, immune privilege of, 201
- Fab antigen-combining sites, 71. *See also* Fragment antigen-binding (Fab)
- F(ab)'₂ fragment, 49
- Fab fragments, 49
- Factor B, 221, 230
- Factor D, 221
- Factor H, 223, 229, 230
- Factor I, 223, 230
- Factor P, 221
- Factor VIII, 22t
- Failure to thrive, 269
- Fanconi anemia, 274
- Farmer's lung, 256
- Fas-associated death domain (FADD), 185, 200
- Fas (CD95), 200
- Fas deficiency, 273
- Fas-Fas ligand (Fas-FasL) interactions, 200
- Fas ligand (FasL), 170, 173, 200
- Fatty acids, 11
- Fc-binding proteins, 336. *See also* Fragment crystallizable (Fc)
- Fc fragment (fragment crystallizable), 49
- Fc receptors, 68
- FcRn protection receptor, 57
- FcRp protection receptor, 57, 57
- FceR1 gene, 234
- FceR1 receptors, 233, 236, 236, 245
- Ferritin, 22t
- Fetus, as tolerated allograft, 309
- Fever, 2, 20, 23
- Fibrinogen, 22t
- Ficolin, 217, 230
- First-set kinetics, 300
- First-set rejection, 300
- First signal, 141, 153, 154, 155
- FK-506 (tacrolimus), 158, 212, 306
- Flow cytometric analysis, 76
- Flow cytometry, 76–77
- Fluorescein isothiocyanate (FITC), 76
- Fluorescence-activated cell sorter (FACS), 77, 77
- Fluorochromes, 84
- f-Met-Leu-Phe receptors, 17
- Follicular B cells, 104
- Follicular dendritic cells, 14, 107
- Follicular lymphoma, 189, 288, 289
- Food allergies, 241, 245
- Foreignness, as requirement for immunogenicity, 35–36
- Foxp3 (forkhead box P3) transcription factor, 199
- Fragment antigen-binding (Fab), 48. *See also* Fab antigen-combining sites
- Fragment crystallizable (Fc), 49. *See also* Fc entries
- Framework regions, 51
- Freund's complete adjuvant, 43
- Functional redundancy, 177
- Fungi, 163
immunity to, 333–334
- Fusion proteins, 307
recombinant, 323
- Fyn tyrosine kinase, 157, 158
- G-protein-coupled receptors, 185
- G proteins, 185, 186
- γδ T cells, 130, 142–143, 145–146, 150, 172, 173
- γ-globulin (gammaglobulin), 48, 49
- Gastrointestinal antigen administration, 38
- GATA3 expression, 181
- Gels, precipitation reactions in, 72, 85
- Gene activation, 312
- Gene amplification, 315
- Gene arrangement, mechanism of, 88

- Gene chips, 83
Gene expression
analysis of, 83–84
control of, 90
review of, 88–90
Gene knock-ins, 83
Gene targeting method, 83
Generalized lymphoproliferative disease (*gld*), 200. *See also gld mice*
Genes, 88
of HLA region, 130–131
Genetic engineering, 9
Genetic predisposition, to autoimmune disease, 202
Genetically altered animals, 81
Genetically engineered molecules/receptors, 80–81
Genome, 88
Genomic databases, 67
Genotype, immunogenicity and, 37
Germinal center, 32, 107
development of T_{FH} and, 166, 166
events in, 105–107, 106, 166–167
thymus-dependent antibody synthesis in, 104
Germline, 91
multiple V genes in, 95
gld mice, 200, 276
Globular domains, of immunoglobulins, 51
Globular structure, 51
Globulins, 47
Glomerular disease, 252
Glomerulonephritis, 23, 208
Glucocorticoid-induced TNF receptor family-related gene (GITR), 199. *See also* Tumor necrosis factor- α (TNF- α)
Glucose-6-phosphate dehydrogenase, 280
Glutamic acid decarboxylase (GAD), 204, 211
Glycolipids, 129
Glycoproteins, 40
Glycosyl phosphatidyl inositol (GPI)-linked membrane molecules, 89
Glycosyl phosphatidyl inositol (GPI) protein deficiencies, 281
Gm allotype marker group, 54
Goiter, 208, 209, 210
Good, Robert, 6
Goodpasture's syndrome, 206t, 209, 252, 253, 255
gp41 glycoprotein, 282, 283
gp120 glycoprotein, 282, 283
Graft rejection, 298
Graft-versus-host (GVH) disease (GVHD), 272, 302, 307, 308
Gram-negative bacteria, 332
Gram-positive bacteria, 332
Granulocyte colony-stimulating factors (G-CSFs), 185, 307, 347
production by and major functions of, 180t
Granulocyte-macrophage CSF (GM-CSF), 185, 237, 347
production by and major functions of, 180t
Granulocytes, 13, 30
Granulomas, 263, 265
Granulomatous hypersensitivity, 259, 262–263, 265
Granulomatous inflammation, 336
Granulomatous vasculitis, 213
Granulysin, 170
Granzymes, 170, 250
Graves' disease, 206t, 207, 207–208, 252
Group A streptococci, 253
Gut-associated lymphoid tissue (GALT), 29, 108, 108, 108, 109, 201
H1 receptors, 237, 238
H2 receptors, 237, 238
H-2 (mouse MHC), 132, 133. *See also* Major histocompatibility complex (MHC)
Haemophilus influenzae, 109, 334
Haemophilus influenzae b, 167, 168, 337, 341
Haplotype, 131
Haptens, 52, 251
immunogenicity and, 35, 36–37, 42
lipids as, 40
Haptoglobin, 22t
Hashimoto's thyroiditis, 206t, 209, 210, 290
Hassall's corpuscle, thymus, 28
Hay fever, 234, 240
Heart, 29
Heat, from inflammation, 20
Heat-shock proteins, 130
Heavy-chain genes, 50, 50t
organization and rearrangement of, 92, 92–93
Heavy-chain (H chain) locus, 92
Heavy (H) chains, 6, 49. *See also* Ig heavy-chain genes; κ -chain entries; λ chain entries; L chain entries; Light chain entries; μ heavy-chain deficiency
association with L chains, 95
complementarity-determining regions of, 51
domains of, 51
structure of, 48–50
HEL (hen egg lysozyme), 196
HEL model, 196
Helicobacter pylori, 289
Helminths, 332, 333
Helper T cells (T_H cells), 7, 104. *See also* T_H entries
B cell presentation of antigen to, 167–168
Hematopoietic cells, 12, 12
developmental pathways of, 12
Hematopoietic stem cell transplantation (HCT), 307–308, 309
Hematopoietin receptor family, 185
Hematuria, 208
Hemoglobinuria, 206
Hemolysis, 336

- Heparin, 237, 238
 Hepatitis A virus (HAV), 337
 Hepatitis B immune globulin (HBIG), 346, 347
 Hepatitis B vaccine, 338
 Hepatitis B virus (HBV), 337
 Hepcidin, 22t
HER-2/neu-1 oncogene, 313
 Herd immunity, 336
 Hereditary angioedema (HAE), 229, 280–281
 Heterologous substances, 41–42
 Heterophile antigens, 42
 Heterozygous molecules, 131
 High endothelial venules (HEVs), 29, 30, 112
 Highly active antiretroviral therapy (HAART), 286–287
 Hinge region, of immunoglobulins, 51
 Histaminase, 238
 Histamine, 237–238
 Histidine, 237
 Histidine-rich glycoprotein (HRG), 252
 Histocompatibility, 117
 Histocompatibility antigens, 301
 Histocompatible individuals, 299
Histoplasma capsulatum, 333, 334
 HIV-1
 binding to CD4 molecule, 141
 genes and proteins of, 284
 HIV genome, 283. *See also* Human immunodeficiency virus (HIV)
 HIV vaccine, 287
 Hives, 235, 241
 HLA-A molecule, 120, 130
 HLA-B molecule, 120, 130
 HLA-C molecule, 120, 130
HLA-DM gene, 131
 HLA-DP molecule, 120, 130
 HLA-DQ molecule, 120, 130
 HLA-DR4 alleles, 212
 HLA-DR molecule, 120, 130
 HLA-DR4 molecule, 130, 131
 HLA-DRB1 association, rheumatoid arthritis and, 212
 HLA-E molecule, 130
 HLA-F molecule, 130
 HLA-G molecule, 130, 309
 HLA haplotypes, 131–132, 132
 HLA region genes, 130–131
 HLA typing, 304
 Hodgkin lymphoma, 293
 Homeostasis, 9
 Homing, 112, 115, 159
 molecules involved in, 141–142, 142
 Homing signature, 142
 Homologous recombination, 83
 Homologous substances, 41–42
 Homozygous molecules, 131
 Hormonal triggers, of autoimmunity, 205
 Horror autotoxicus, 201
 Host defense strategy, 3
 Host-microbe interaction, potential outcomes in, 329, 329–330
 Human chorionic gonadotropin (HCG), 72
 Human epidermal growth factor receptor (HER), 313
 Human genome, sequencing, 2
 Human herpes virus 8 (HHV-8), 285
 Human immune serum globulin
 comparison of, 346t
 preparation and properties of, 346
 Human immune serum globulin therapy, precautions on uses of, 347
 Human immunodeficiency virus (HIV), 10, 133, 184, 282–287, 294, 333. *See also* HIV entries
 clinical course of, 284–286
 diagnosis of, 74
 prevention, control, diagnosis, and therapy of, 286–287
 structure of, 283
 vaccines against, 42
 Human immunodeficiency virus (HIV)-1, 171
 Human leukocyte antigen (HLA), 118, 202. *See also* HLA entries
 Human microbiome, 108
 Human papillomavirus (HPV), 285, 315, 337
 vaccines, 42, 342
 Human papillomavirus (HPV) capsid protein L1 vaccine, 321
 Human retinal pigment epithelial (RPE) cells, 201
 Human T-cell lymphotropic virus type 1 (HTLV-1), 133, 292, 315
 Human X-linked hyper-IgM syndrome, 112
 Humanized antibodies, 80
 Humoral acute rejection, 300
 Humoral immune defense system, 20
 Humoral immunity, 6, 26, 269, 331
 Hybridoma/monoclonal antibody technology, 79
 Hybridoma technology, 345
 Hybridomas, 48
 Hydrogen bonds, 6
 Hydrolytic enzymes, 11
 Hydrophobic forces, 68, 84
 Hydrophobic haptens, 52
 Hydrophobic interactions, 6, 41
 Hyper-IgM (HIGM) syndrome, 107, 273, 278
 Hyperacute rejection, 300
 Hypersensitivity. *See also* Hypersensitivity reactions
 contact, 259, 261–262, 262, 265
 delayed-type, 234
 granulomatous, 259, 262–263, 265
 immediate, 233, 236
 tuberculin-type, 259, 263, 263–264, 265
 type I, 233–245, 240
 type II, 233, 249–252, 250, 256
 type III, 233–234, 249, 252–256
 type IV, 162, 234, 259–265
 Hypersensitivity designations, 233–234

Hypersensitivity reactions, 9
examples of, 251–252
IgE in, 62, 244
vaccines and, 342

Hyperthyroidism, 207, 208

Hypervariable regions, 51–52

Hypesthesia, 210

Hypoemia, 335

Hypotension, 335

Hypoxanthine guanine phosphoribosyl transferase (HGPRT), 80

I-A molecule, 132

I-E molecule, 132

Iatrogenic immunodeficiency, 283

ICAM-3 molecule, 141, 142, 156

iC3b opsonin, 223, 224

ICOS-ICOS ligand, 167. *See also* Inducible costimulatory molecule (ICOS)

ICOS-ICOSL interaction, 167

ICOSL molecule, 112. *See also* Inducible costimulatory (ICOS) ligand (ICOSL)

Idiopathic thrombocytopenia purpura (ITP), 201, 206t

Idiotypes, 54–55

Idiotypic regions, 54

Ig, comparison of $\alpha\beta$ TCR and, 138, 139t

Ig allotypes, 55. *See also* Immunoglobulin entries

Ig chains, genetic events in synthesis of, 90–94

Ig gene expression, regulation of, 93–94

Ig gene superfamily, 138

Ig genes, 287

Ig heavy-chain genes, 50, 50t

Ig idiotypes, 55

Ig isotypes, 53, 53t, 55

Ig superfamily, 138
members of, 63, 63

IgA, 50, 50t

IgA antibody, 64. *See also* Immunoglobulin A (IgA)

IgA deficiency, 277

IgA proteases, 336

IgA synthesis in mucosa, 108, 108–109

Ig α (CD79a) molecules, 102, 111

Ig β (CD79b) molecules, 102, 111

IgD, 50, 50t. *See also* IgM+ IgD+ mature B cell; Immunoglobulin D (IgD)

IgE, 50, 50t

IgE antibody, 242. *See also* Immunoglobulin E (IgE)

IgE antibody production, T_H2 cell dependency of, 234–235

IgE Fc receptor gene, 234

IgE levels, worm infections and, 333

IgE-mediated hypersensitivity, 244

IgG, 50, 50t

IgG antibodies, 57, 62, 242, 340

IgG class autoantibodies, 206

IgG isotype, passage through the placenta, 56–57

IgG molecules. *See also* Immunoglobulin G (IgG)
agglutination and formation of precipitate by, 56
antibody-dependent, cell-mediated cytotoxicity and, 58
bacteria immobilization by, 58
complement activation and, 58
toxin and virus neutralization by, 58

IgG subclasses, differences among, 53, 53t

IgM antibodies, 60, 62, 64, 105. *See also* Immunoglobulin M (IgM)
avidity of, 70

IgM cold agglutinins, 206

IgM deficiency, 277

IgM+ IgD+ mature B cell, 104

IgM isoagglutinins, 60

IgM molecule, 59
agglutination and, 60
complement fixation and, 59
neonatal immunity and, 59

IgM pentamers, 70

IL-21, 165

IL-12/23-interferon- γ deficiency, 280

IL-1 cytokine, 21, 23, 177, 179, 180t, 183. *See also* Interleukin

IL-2 cytokine, 177, 180t, 186

IL-3 cytokine, 180t, 185, 237

IL-4 cytokine, 180t, 186, 237

IL-5 cytokine, 180t, 237

IL-6 cytokine, 179, 180t, 183

IL-7 cytokine, 144–145, 180t, 185, 186

IL-8 cytokine, 21, 237

IL-9 cytokine, 180t, 186, 237

IL-10 cytokine, 180t, 183, 200

IL-11 cytokine, 180t

IL-12 cytokine, 180t

IL-13 cytokine, 180t

IL-14 cytokine, 180t

IL-15 cytokine, 180t, 186

IL-16 cytokine, 180t

IL-18 cytokine, 180t

IL-23 cytokine, 180t, 183

IL-2 cytokine receptor, 186, 187

IL-17 family of cytokines, 180t, 182, 182t

IL-2 receptor, 158, 159

IL-1 receptor antagonist (IL-1Ra), 190

IL-2 receptor (IL-2R), 190

IL-2 receptor α chain, 158, 159

Immature B cells, 103–104, 119
responses to self-antigens, 103

Immature dendritic cells, 154–155

Immediate hypersensitivity, 233, 236

Immune-based diseases, 189

Immune complex disease
infection-associated, 253, 255
localized, 252, 255–256
systemic, 252, 253, 255

- Immune complex reactions, 233
 Immune complexes, 252
 controlling formation and creation of, 225
 Immune disorders, clinical manifestations of, 269t
 Immune dysregulation polyendocrinopathy enteropathy
 X-linked (IPEX) syndrome, 164, 199
 Immune globulin, indications for use of, 346–347. *See also*
 Immunoglobulin entries
 Immune privileged sites, 201, 213
 Immune response(s)
 damaging effects of, 9
 evocation of, 35
 generation of diversity in, 8
 limitations of effectiveness of, against tumors, 320
 primary and secondary, 38
 type-2, 333
 Immune system
 evolution of, 11
 overview of, 1–10
 suppression of, 336
 Immune thrombocytopenia purpura (ITP), 252
 Immunity
 acquired, 14
 adaptive, 2–3, 2t, 26–33
 to bacteria, 331–332
 cell-mediated, 7–8, 82, 162, 331, 332
 cellular, 6, 26
 to fungi, 333–334
 humoral, 6, 26, 331
 innate, 2–3, 2t, 11–24
 to parasites, 332–333
 to viruses, 330–331
 Immunization(s), 3. *See also* Vaccines
 active, 5, 337, 348
 age and timing of, 339–341
 kinetics of antibody responses following, 62–63
 objectives of, 337
 passive, 5, 58, 82, 337, 344–347, 348
 principles of, 336–337
 recommended, 337
 Immunoabsorption, 78
 Immunoadsorption, 78
 Immunoassays, 74–76
 direct-binding, 74–75
 solid-phase, 75–76
 Immunoblots, 73–74, 74
 Immunocompromised patient, vaccine hazards and, 341
 Immunocytokines, 323
 Immunodeficiencies, treatment of, 190
 Immunodeficiency diseases, inborn, 268
 Immunodeficiency patients, malignant neoplasms with
 increased incidence in, 316t
 Immunodeficiency syndromes, 269–274
 Immunodiagnosis, 320–321, 325
 Immunodominant epitopes, 124
 Immunodysregulation polyendocrinopathy enteropathy
 X-linked syndrome (IPEX), 276
 Immunoediting hypothesis, 316
 Immunoelectrophoresis, 73, 73
 Immunofluorescence, 76, 85
 Immunogenicity, 44
 requirements for, 35–38
 Immunogens, 35, 42, 251
 Immunoglobulin A (IgA), 56. *See also* IgA entries; Immune
 globulin
 structural and biologic properties of, 60–61
 Immunoglobulin-associated immunodeficiency
 disorders, 276–277
 Immunoglobulin class switching, 27
 Immunoglobulin D (IgD), 56, 64. *See also* IgM+ IgD+
 mature B cell
 structural and biologic properties of, 61
 Immunoglobulin E (IgE), 56, 64. *See also* IgE entries
 in parasitic infections and hypersensitivity reactions,
 62
 structural and biologic properties of, 62
 Immunoglobulin-fold domains, 49, 63, 63
 Immunoglobulin G (IgG), 56, 64. *See also* IgG entries
 biologic properties of, 55
 prolonged survival of, 55
 structural features of, 55
 Immunoglobulin G₁ (IgG₁), 55
 Immunoglobulin G₂ (IgG₂), 55
 Immunoglobulin G₃ (IgG₃), 55
 Immunoglobulin G₄ (IgG₄), 55
 Immunoglobulin gene structure, review of, 88–90
 Immunoglobulin isotopes, most important features of,
 53t
 Immunoglobulin M (IgM), 50, 50t, 56, 62, 64
 biologic features of, 59–60
 structural features of, 59
 Immunoglobulin superfamily, 49, 63, 63
 Immunoglobulin superfamily receptors, 185, 186
 Immunoglobulin variants, 53–55, 55
 allotypes, 54, 55
 idiotypes, 54–55, 55
 isotypes, 53, 55
 Immunoglobulins (Ig), 6, 47. *See also* Ig entries; Membrane
 immunoglobulin; Poly-Ig receptor
 classes of, 50, 50t
 concentration of, during human development, 340
 constant region of, 50, 51
 globular structure of, 51
 hinge region of, 51
 isolation and characterization of, 48
 variable region of, 51–52
 Immunologic intervention, against allergies, 242–244
 Immunologic synapse, 156
 formation of, 156–157

Immunologically privileged sites, 309
Immunology. See also Clonal selection theory; Tumor immunology
benefits of, 8–9
development of, 1–2
future of, 9–10
Immunology: Clinical Case Studies and Disease Pathophysiology (Strober and Gottesman), xviii, xxii, xxvi
Immunophilins, 306
Immunoprophylaxis, 8, 10, 321–322, 325, 339, 348
Immunoreceptor tyrosine-based activation motifs (ITAMs), 102, 139
phosphorylation of, 157–158
Immunoreceptor tyrosine-based inhibitory motif (ITIM), 114
Immunostimulatory monoclonal antibodies, 323
Immunosuppressive antibody therapy, 306
Immunosuppressive drugs, 305, 305t
Immunosuppressive strategies, new, 306–307
Immunosuppressive therapy, 265, 304–307, 341
Immunosurveillance, 312, 316
Immunotherapies, 293, 322, 322–323, 325, 348
in silico analyses, 67
in vitro systems, 79
in vitro techniques, 67
in vivo animal models, 67
in vivo systems, 81
Inbred strains, 132
animal, 81–82
Indirect Coombs test, 71
Indirect immunofluorescence, 76
Indirect mechanism, of T-cell alloantigen recognition, 302, 302, 309
Inducible co-stimulatory (ICOS) ligand (ICOSL), 112.
See also ICOSL molecule
Induction therapy, 305
Inductive site, 108
Induration, 262, 263, 263, 265
Infection-associated immune complex disease, 253, 255
Infection(s), 329
mucosal, 60–61
parasitic, 62
recurrent, 269, 276, 293
routes of, 11–12
Infereron receptor family, 185
Inflammasome, 17
Inflammation, 15, 20–23
chronic, 23
factors in, 20
granulomatous, 336
signs of, 20–21
Inflammatory bowel disease, 21
Inflammatory effects, of T cell subsets, 7
Inflammatory mediators, 237

Inflammatory responses
local, 21–23
localized, 21–23
systemic, 20–21
Inflammatory T_H2 cells, 178
Influenza virus, 168, 337–338, 341
Inhibitors, cytokine, 189–190
Innate defense mechanisms, 333
Innate immune responses
cytokines that facilitate, 179–181
pattern recognition and, 15–18
Innate immune system
major properties of, 2t
origin, differentiation, and characterization of cells
of, 12–15
Innate immunity, 2, 11–24
comparison of specificity and cellular distribution of receptors used in, 16
physical and chemical barriers of, 11–15
relationship with adaptive immunity, 33, 33
role of, 11
Innate lymphoid cells (ILCs), 15, 172, 173
Innate receptors, 2
Insulin-dependent diabetes mellitus (IDDM), 211, 211
Integrase, 283
Integrins, 112, 150
Intercellular adhesion molecule 1 (ICAM-1), 156, 241
Interdigitating cells, of thymus, 14
Interferon- α (IFN- α), 179, 181
Interferon- β (IFN- β), 179, 181
Interferon- γ (IF- γ , IFN- γ), 15, 261, 261
production by and major functions of, 180t
Interferon receptor family, 185
Interferon regulatory factor (IRF)-responsive genes, 17
Interferons, 2, 11, 181
Interfollicular (T cell) zone, 32
Interleukin, 177. *See also* IL entries
Internal image, 54
Intracellular bacterial pathogens, 332
Intracellular signaling pathways, activation of, 158
Intracellular survival, 335–336
Intraepithelial lymphocytes (IEL), 108
Intranasal antigen administration, 38
Intravenous antigen administration, 38
Intravenous γ -globulin (IVGG), 276, 347. *See also* IVIG/IVGG preparations
Intrinsic asthma, 241
Introns, 88
Invariant chain (Ii, CD74), 124
Invariant region, 122
Ischemia, 226
Islets of Langerhans, insulin-dependent diabetes mellitus and, 211, 211
Isograft, 299, 299
Isohemagglutinins, 60, 251

- Isotopes, subclasses, 50
 Isotype switching, 94–95
 Isotypes, 50, 55
 Ig, 53
 IVIG/IVGG preparations, 346. *See also* Intravenous γ -globulin (IVGG)
- J chain, 56, 59
 JAK kinases, 187, 188, 192
 Jenner, Edward, 3, 337
 Jerne's network theory for immune regulation, 54
 Joining (J) gene segment, 90
 Junctional diversity, 95
- Kaposi sarcoma (KS), 285
 κ -chain synthesis, 91–92
 κ chains, 50. *See also* Light (L) chains
 κ L chain, gene rearrangement and subsequent steps in synthesis of, 90
 κ -locus, 91
 Ketoacidosis, 211
 Killer-cell inhibitory receptors (KIRs), 14, 309
 Killer T cells, 153, 168. *See also* Natural killer T (NKT, NK/T) cells
 Kinases, activation of, 157–158
 Kinins, 21, 222
Klebsiella pneumoniae, 163
 Km allotype marker group, 54
 Knockout mice, 81, 83, 272
 Kupffer cells, 13, 252
- L-chain gene rearrangement, 104. *See also* λ chain entries; Light chain entries
 L-selectin, 23, 142
 LAD1 disorder, 279. *See also* Leukocyte adhesion deficiency (LAD); Leukocyte adhesion deficiency I
 LAD2 disorder, 279
 LAD3 disorder, 279
 λ_5 chain deficiency, 277
 λ -chain synthesis, 91
 λ -chains, 50. *See also* L chain entries
 λ 5 gene, 102
 Lamina propria, 60, 108, 108
 Langerhans cells, 14, 154, 262
 Late-phase reactions, 238
 of allergic responses, 237, 238–240
 Latency, 330
 Latent or lag phase, in primary response, 62
 Lattice, 72
 Layering, 328
 Lck tyrosine kinase, 157, 158
 Leaky SCID, 272
 Lectin activation pathway, 18, 18
 Lectin complement activation pathway, 217, 218, 219–220, 220, 230
- Lectins, 78
 Lethal toxin (LT), 334
 Leukemia, 287
 Leukocyte adhesion deficiency I, 228
 Leukocyte adhesion deficiency (LAD), 278–279
 Leukocyte function-associated antigen 1 (LFA-1), 89, 156, 241. *See also* LFA entries
 Leukocyte movement, cytokines that affect, 183–184
 Leukocytes
 adhesion to endothelium, 22
 polymorphonuclear, 12, 13, 13, 20
 transendothelial migration of, 21–23
 Leukotriene modifiers, 243t, 246
 Leukotrienes (LTs), 238, 240
 LFA-1 molecule, 112, 141, 156, 279. *See also* Leukocyte function-associated antigen 1 (LFA-1)
 LFA-3 molecule, 156
 Licensing, 169
 Ligand, 69
 Ligand creation, by MHC molecules, 124–129
 Light-chain genes, organization and rearrangement of, 90
 Light (L) chains, 6, 49. *See also* Heavy chain entries; κ -chain entries; λ chain entries; L chain entries
 association with H chains, 95
 complementarity-determining regions of, 51
 domains of, 51
 structure of, 48–50
 Lineage choice, 146, 147
 Lineage-specific T-cell differentiation, cytokines that inhibit, 182
 Linear B-cell epitopes, 39, 39
 Linear T-cell epitopes, 39
 Linked recognition, 167, 167, 173
 Linker for activation of T cells (LAT), 158
 Lipases, 19
 Lipid rafts, 157
 Lipids, 129
 as antigens, 40
 presented by CD1 and NKT cells, 120
 Lipopolysaccharide (LPS), 43, 78, 332
 Localized immune complex disease, 252, 255–256
 Localized inflammatory responses, 21–23
 Long terminal repeat (LTR) region, of HIV genome, 283
lpr mice, 200, 276
 LTb4, 238
 LTC4, 238
 LTD4, 238
 LTE4, 238
 “Lumpy-bumpy” deposits, 255, 255
 Lung, degranulation of mast cells in, 235
 Lymph nodes, 29
 differentiation to effector T cells and migration out of, 159
 section of, 32
 T cell-B cell interactions in, 105, 106
 Lymphatic organs, in adaptive immunity, 27–29

Lymphatic vessels, in spleen, 29
Lymphocyte activating factor (LAF), 176, 177
Lymphocyte choriomeningitis virus (LCMV), 168
Lymphocyte function assays, 78
Lymphocytes, 238. *See also* B lymphocytes; T lymphocytes
 antigen-specific, 26
 antigen-specific naïve, frequency of, 32–33
 autoreactive, 195, 197
 homing of, 112
 migration and recirculation of, 29–31
Lymphoepithelial organ, 28
Lymphoid cancers, 189, 192
Lymphoid cell lines, cloned, 79–80
Lymphoid neoplasms, 287, 294
 World Health Organization classification for, 287, 288t
Lymphoid tissue-inducer (LTi) cells, 15
Lymphoid tissues, distribution in the body, 27
Lymphokine-activated killer (LAK) cells, 190–191, 318
Lymphokines, 176
Lymphoma
 follicular, 288
 lymphoplasmacytic, 291
 mantle cell, 289
 marginal zone, 289–290
Lymphoplasmacytic lymphoma, 291
Lysis, 58, 230
 bacterial, 331
 of pathogens, 225, 226
Lysozymes, 11
LYST gene, 279

M cells, 108
M spikes, 291
Macroblobulin (M), 59
Macrolides, 306
Macrophage CSF (M-CSF), 184, 347
 production by and major functions of, 180t
Macrophages, 5, 12, 13, 26, 109, 129, 238, 261, 332
 functions of, 14
 histologic forms of, 13
 tumor cell destruction by, 318–319, 319
Macular degeneration, age-related, 222, 230
Maintenance therapy, 305
Major basic protein (MBP), 239
Major histocompatibility complex (MHC), 5, 82, 191, 264, 331. *See also* MHC entries; Polymorphic MHC entries
 derivation of, 117–118
 human, 120, 120
 in nonhuman species, 132
 role in antigen presentation, 118, 118–119
Major histocompatibility complex (MHC)-bound peptides, 26
Major histocompatibility complex (MHC) class II molecules, 111

Major histocompatibility complex (MHC) molecules, 117
Malaria, 9
 vaccines against, 42
Malignant neoplasms, with increased incidence in immunodeficiency patients, 316t
Mannan-binding lectin (MBL), 22t, 180, 181, 217
Mannose-associated serine proteases (MASPs), 219–220
Mannose-binding lectin deficiencies, 280
Mantle cell lymphoma, 289, 289
Mantle zone, 32, 106
Marek's disease, 133, 322
Marginal-zone B cells, 104, 109
Marginal-zone lymphoma, 289, 289–290
Masks, 242
Mast cell degranulation, 236, 236
Mast cells, 5, 233, 234, 235, 235, 237, 237, 241, 245, 333
Maternal antibodies, 340, 341
Mature B-cell neoplasms, 288–291
Mature B cells, 93, 104, 119
Mature dendritic cells, 155
Mature T-cell neoplasms, 292–293
Matzinger "danger hypothesis," 7
Medawar, Peter, 195
Mediators
 newly synthesized, 237, 238
 preformed, 237, 237–238
Medulla, 28, 29, 144, 145
Melanoma, contact point between activated macrophage and, 319
Melanoma-associated antigen (MAGE) proteins, 314
Membrane attack complex (MAC), 18, 58, 218, 222, 222, 230, 280
Membrane-bound antibodies, 47
Membrane cofactor protein (MCP), 223
Membrane immunoglobulin, 111
Membranoproliferative glomerulonephritis, 228
Memory, 100
 in adaptive immune response, 5
Memory B cells, 105
Memory CD8+ cells, 171
Memory cells, 26, 38, 62, 107
Memory responses, 3, 38
Memory T-cell responses, 171
Memory T cells, 142, 149, 171
Mercaptoethanol, 49
Mercaptourine, 305
Messenger RNA (mRNA), 83, 84, 84, 88, 89
Metalloproteinases, 210
Methylprednisolone, 305
Meyloid dendritic cells, 154
MHC class I, structure of, 120–122, 121
MHC class I expression, in virus-infected and tumor cells, 127

- MHC class I molecules, 119, 131, 138, 146, 168, 170, 301
 CD8 binding to invariant region of, 122
 comparison of properties and functions with MHC class II molecules, 128t
 selectivity of peptide binding to, 121–122
 structure of, 40
 variability of, 119–120
- MHC class I pathway, exogenous antigens presented in, 127–128
- MHC class I-peptide complexes, generation of, 126–127
- MHC class II molecules, 119, 131, 138, 146, 154, 155, 165, 332
 comparison of properties and functions with MHC class I molecules, 128t
 interaction with CD4 co-receptor, 156
 structure of, 122, 123
 variability of, 119–120
- MHC class III region genes, 131
- MHC-disparate mouse strain, 300
- MHC gene expression, regulation of, 131–132
- MHC genes, inheritance of, 131–132
- MHC molecules
 diversity of, 122, 132–133
 ligand creation by, 124–129
 peptide binding by, 121–122, 124–129
 role in allograft rejection, 301–302
- MHC restriction killer function, 170–171
- MHC restriction of T-cell responses, 118
- MICA* gene, 130
- MICB* gene, 130
- Microarrays, to assess gene expression, 83–84, 84
- Microbes, 329
- Microbial pathogens, host defense against classes of, 330–334
- Microdomains, 157
- Microglial cells, 11, 13
- Microorganisms
 intracellular and extracellular killing of, 19–20
 intracellular survival and, 335
- Minor H antigens, 302
- MIP-1 α chemokine, 184
- MIP-1 β chemokine, 184
- Mitogen-activated protein (MAP) kinases, 158
- Mitogen-associated protein kinases (MAPKs), 17
- Mitogenic antigens, 109
- Mitogenic stimulation, 78
- Mitogens, 78, 160
- Mixed leukocyte reaction (MLR), 304, 304t, 309
- Molecular biologic techniques, 8
- Molecular mimicry, 204, 204, 214
- Molecular typing of donor and recipient, 303
- Molecular weight, as requirement for immunogenicity, 36
- Molecules, genetically engineered, 80
- Monoclonal anti-CTLA-4 antibody, 323
- Monoclonal antibodies, 80, 81, 85, 105, 306
 immunostimulatory, 323
 tumor-specific, 322
- Monoclonal antibody preparations, 345–346
- Monoclonal antibody technology, 2
- Monoclonal antibody therapy, 213, 214
- Monocytes, 12, 13, 30
- Monokines, 176
- Monomeric IgA, 60
- Mouse MHC class I genes, 132. *See also* Major histocompatibility complex (MHC)
- Mucosa-associated lymphoid tissue (MALT), 29, 32, 60, 105, 108, 109, 283, 290
- Mucosal infections, IgA role in, 60–61
- Mucosal tissue, antibody synthesis in, 107–109
- Mucous membrane barrier, 11
- Multiple myeloma, 48, 291
- Multiple sclerosis (MS), 206t, 210–211, 213
- Multisystem disorders, 273–274
- Mutant cellular gene products, 314–315, 314t
- Mutation, 312
- μ heavy-chain deficiency, 277
- Myasthenia gravis, 206–207, 206t, 207, 252
 “floppy baby” newborns and mothers with, 202
- Mycobacteria, 332
- Mycobacterium africanum*, 264
- Mycobacterium bovis*, 264
- Mycobacterium butyricum*, 43
- Mycobacterium tuberculosis*, 43, 129, 263, 264
- Mycophenolate mofetil, 305
- MyD88, 17
- Myelin basic protein (MBP), 210
- Myelin oligodendrocyte protein (MOG), 210
- Myeloid cancers, 189
- Myeloma proteins, 48
 detection of, 321
- Myeloperoxidase, 20, 280
- Myocardial infarction, 222
- Myocarditis, autoimmune, 203
- N-formylmethionine (fMet), 17
- N-myc oncogene, 315t
- N-nucleotides, 95
- NADPH oxidase, 280
- Naïve B cells, 104
- Naïve T cells, 141, 142, 148
 dendritic cells as key APC for, 153–155
- Natalizumab, 213
- Natural killer cell deficiency, 280
- Natural killer (NK) cells, 14, 162, 171–172, 173, 268, 330.
See also Natural killer T (NKT, NK/T) cells
 destruction of tumor cells by, 318
 differentiation of, in the thymus, 149, 150
 effector cell assays for, 79
 inhibitory receptors and killing, 14

- Natural killer T (NKT, NK/T) cells, 14–15. *See also* Natural killer cell entries
differentiation of, in the thymus, 149
Necrotic cells, removing, 225–226, 227, 230
Negative BCR signal modulation, 113–114. *See also* B-cell receptors (BCRs)
Negative selection, 103, 146, 147–148, 148, 150, 195, 195
role of AIRE gene product in, 148
Neisseria meningitidis, 334
Neisseria meningitidis vaccine, 338
Neonatal hyperthyroidism, transient, 208
Neonatal immunity, IgM antibodies and, 59
Neonatal tolerance, 194, 195
Neoplasms
B-cell, 288–291
lymphoid-system, 189, 192, 287, 288t
malignant, 316
mature B-cell, 288–291
T-cell, 291–293
Nephelometry, 72
Neutralization of toxins and viruses, IgG molecule and, 58
Neutralizing antibodies, 331
Neutrophil chemotaxis, 178, 179
Neutrophil transendothelial migration, 183, 183
Neutrophils, 5, 6, 12, 13, 183, 238, 263
tumor cell destruction by, 318–319
Newly synthesized mediators, 237, 238
NF-AT transcription factor, 158
NF-κB transcription factor, 113, 158
Nippostrongylus brasiliensis, 234
NK-cell activity, 127. *See also* Natural killer (NK) cells
NK cell deficiency, 269t
NK/T cells, destruction of tumor cells by, 318
NOD-like receptors (NLRs), 16, 17
Nomenclature Committee of the International Union of Immunologic Sciences, CD number assignment by, 77
Non-HLA genes, 202. *See also* Human leukocyte antigen
Noncovalent binding, 41
Nonhistocompatible individuals, 299
Nonobese diabetic (NOD) mouse, 211
Nonpeptide antigens, TCR interactions with, 129, 130
Nonpolymorphic region, 122
Nonself peptide, 146
Nuclear factor kappaB (NF-κB), 17
Nucleases, 19
Nucleic acids, as antigens, 40–41
Nucleotides, 19
Nude mice, 144
NZB/W F1 mouse strain, 209
Obligate intracellular pathogens, 330
OKT3 mouse monoclonal antibody, 306
Omenn syndrome, 271t, 272
Oncofetal antigens, 313
Oncogene theory, 315
Oncogenes, 313
tumor antigens encoded by, 315
Oncogenic viruses, 315
Opportunistic infections, 269, 275, 286
Opportunistic pathogens, 330
Opsonins, 19, 57, 217, 226, 230
production of, 217–218, 224–225
Opsonization, 57–58, 217, 226, 249, 331, 332
complement-mediated, 47
tumor cell destruction by, 318
Opsonized antigens, 18
Opsonized bacteria, 18
Oral tolerance, 200–201, 213
Organ failure, 335
Organs, transplantation of, 308
Orosomucoid, 22t
Osteoblasts, 177
Osteoporosis, 177
Ovary, immune privilege of, 201
Owen, Ray, 195
p24 core antigen, 282
p17 matrix protein, 282, 283
p7 nucleoprotein, 282
P-nucleotides, 95
p53 protein, 314
P-selectin, 23
Pain, from inflammation, 20
Papain, 48, 49
Paracrine cells, 177, 178
Paramyxovirus, 228
Parasites, immunity to, 332–333
Parasitic infections, IgE in, 62, 244, 244, 245, 246
Paratopes, 39
Paroxysmal nocturnal hemoglobinuria (PNH), 229, 281
Partial lipodystrophy, 229
Particulate antigen, 70
Passive agglutination, 71
Passive antibody therapy, 344–345
Passive cutaneous anaphylaxis (PCA), 235
Passive immunization, 5, 58, 82, 337, 344–347, 348
Passive transfer, 82
Pasteur, Louis, 3
Patch test, 262
Pathogen-associated molecular patterns (PAMPs), 15, 17, 204, 205
Pathogenicity, 328
Pathogens
elimination of, 329, 329
opportunistic, 330
Pattern of identity, 73
Pattern of nonidentity, 73
Pattern recognition, 15–18

- Pattern recognition receptors (PRRs), 15–16, 155
 C-type lectin receptors, 17
 f-Met-Leu-Phe receptors, 17
 NOD-like receptors, 17
 RIG-I-like receptors, 17–18
 toll-like receptors, 16–17
 PCR fingerprinting, 303. *See also* Polymerase chain reaction (PCR)
 Pelvic inflammatory disease, 21
Pemphigus vulgaris, 206t, 209, 213, 252
 Pepsin, 49, 49
 Peptide-based vaccines, 42
 Peptide binding
 by MHC molecules, 121–129
 selectivity to MHC class I molecules, 121–122, 122
 Peptide-binding groove, 121
 Peptide/MHC interaction with TCR, 155–156
 Peptides, 9, 19
 Peptidoglycan, 332
 Perforin, 170, 250
 Pericarditis, autoimmune, 203
 Periodontal disease, 177
 Peripheral T-cell lymphomas, 292
 Peripheral tolerance, 194, 197–200, 213
 Peritoneal macrophages, 13
 Pernicious anemia, 206t
 Persistence, 330
 Peyer's patches, 29, 108, 108, 109
 Phagocytes
 pattern recognition receptors and, 15
 protective enzymes produced by, 11
 Phagocytic cell deficiency, 269t
 Phagocytic cells, 20, 332, 335
 Phagocytic dysfunctions, 278–280
 Phagocytic polymorphonuclear (PMN) cells, 6
 Phagocytosis, 19–20, 58, 252, 331, 332, 333
 macrophages and role in, 13
 of particle coated with antibodies, 58
 tumor cell destruction by, 318
 Phagolysosome, 19
 Phagosome, 19
 Pharmacological intervention, against allergies, 242, 243t
 Philadelphia chromosome, 314
 Phosphamide, 212
 Phosphatidylinositol-3 (PI₃) kinase, 158
 Phosphoantigens, 143, 172
 Phospholipase, 113
 Phospholipase C-γ (PLC-γ), 158
 Phytohemagglutinin (PHA), 78, 160
 Picornavirus family, 228
 Pinocytosis, 19
 Placenta, immune privilege of, 201
 Placental antibody transfer, passive immunization through, 344
 Placental transfer, of IgG, 56–57
 Plant proteins, 160
 Plasma cell myeloma, 291
 Plasma cell neoplasms, 291
 Plasma cell tumors, detection of myeloma proteins produced by, 321
 Plasma cells, 104–105, 107
 Plasmacytoid dendritic cells (pDC), 14, 154
 Plasmaphoresis, 300
 Plasminogen, 22t
 Platelet-activating factor (PAF), 238, 240
 Platelet-activating-factor receptor, 186
 Platelet-derived growth factor (PDGF), 253
 Pleiotropic properties, 177
 Pneumococcal polysaccharide vaccine, 341
 Pneumovax, 168
 Point mutation, 315
 Poison ivy, 261, 262
 Poison ivy dermatitis, 262, 262
 Pokeweed mitogen (PWM), 78, 160
 Polarized immune response, 164–165
 Poliomyelitis, 8
 Poly-Ig receptor, 60. *See also* Immunoglobulins (Ig)
 Polyclonal activation, 214
 Polyclonal activators, 160, 204, 204
 Polyclonal antibody preparations, 345–346
 Polyclonal antiserum, 4
 Polyclonal B-cell activators, 109
 Polyclonal response, 105
 Polygenic MHC, 120. *See also* Major histocompatibility complex (MHC)
 Polygenicity, 119
 Polymerase chain reaction (PCR), 80. *See also* PCR fingerprinting
 Polymeric proteins, 38
 Polymorphic MHC antigens, 298
 Polymorphic MHC molecules, nomenclature of, 131
 Polymorphic region, 122
 Polymorphism, 119, 120
 Polymorphonuclear leukocytes, 12, 13, 13, 20
 Polyoma, 315
 Polysaccharide capsules, 334
 Polysaccharides, as antigens, 39, 40
 Polyspecific antibodies, 110
 Positive BCR signal modulation, 113. *See also* B-cell receptors (BCRs)
 Positive selection, 146–147, 147, 150
 Postcapillary venules, 29
 Prausnitz-Kustner (P-K) test, 235
 Pre-B cell receptor (pre-BCR), 102–103, 102. *See also* B-cell receptors (BCRs); Precursor B-cell lymphoblastic leukemia/lymphoma (B-ALLs)
 Pre-B cells, 101, 110
 Pre-T cell receptor (pre-TCR), 146
 Pre-T cells, 146

Pre-T α cells, 146
Precipitates, 56
Precipitation, 67
Precipitation reactions, 72–74, 85
 in gels, 72, 85
 in solutions, 72, 85
Precipitin curve, zones of, 72, 72
Precipitin reaction, 72, 72
Precursor B-cell lymphoblastic leukemia/lymphoma (B-ALLs), 288. *See also* Pre-B-cell entries
Precursor cells, 27
Precursor T-cell acute lymphoblastic leukemia/lymphoma (T-ALL), 291–292
Prednisolone, 305
Prednisone, 305
Preformed antibodies, 300
Preformed mediators, 237, 237–238
Pregnant women, transplacental passage of IgG and, 212
Primary cell cultures, 79–80
Primary effusion lymphoma, 285
Primary immune response, 38
Primary immunization, 38
Primary immunodeficiencies, 269, 293
Primary immunodeficiency syndromes, 270–274, 273
Primary lymphoid follicles, 29
Primary lymphoid organs, 27, 27, 101
Primary response, 64
 incubation period and, 340
 significance of, 339
Primary response, phases of, 62
Primary RNA transcripts, 89, 97
Pro-B cells, 101, 110
Productive gene rearrangement, 102
Programmed cell death, 102, 195. *See also* Apoptosis
Programmed cell death protein (PD)-1, 159
Programmed death ligand (PD-L) 1, 160
Programmed death ligand (PD-L) 2, 160
Proinflammatory cytokines, 163, 183
Properdin, 221
Prophylaxis, 8
Prostaglandins, 238
Prostate-specific antigen (PSA), detection of, 321
Protease inhibitors, 286
Proteases, 19
Proteasome, 126
Protection mechanisms
 immunizations, age and timing of, 339–341
 primary and secondary responses, 339
Protein A, 336
Protein antigens, processing and presentation of, 118
Protein G, 336
Protein kinase C (PKC), 113, 158

Proteins
 acute-phase, 20, 22t, 23, 179
 adaptor, 17
 as antigens, 41
 Bence Jones, 48, 321
 clonotypic, 313
 in complement cascade, 19t
 FC-binding, 336
 fusion, 307
 heat-shock, 130
 MAGE, 314
 myeloma, 48, 321
 organizational structure, levels of, 37
 plant, 160
 polymeric, 38
 recombinant fusion, 323
 soluble, 11
Proteinuria, 208
Proteolipid protein (PLP), 210
Proteomic databases, 67
Proteosomes, 301
Prothrombin, 22t
Proto-oncogenes, cellular, 315, 315t
Protozoa, 332, 333
Prozone, 70, 85
Pseudogenes, 96, 96
Psoriasis, 206t, 212
Public idiotypes, 55
Purified protein derivative (PPD), 263, 264
Purine nucleoside phosphorylase deficiency, 271t, 272
Purine nucleoside phosphorylase (PNP), 272
Pyogenic bacteria, 228
Pyogenic organisms, 279
Quaternary protein structure, 36
Rabies immune globulin (RIG), 346
Radial immunodiffusion test, 72, 73, 73, 85
Radioallergosorbent test (RAST), 242
Radioimmunoassay (RIA), 74, 74–75
Radiosensitivity SCID, 272. *See also* Severe combined immunodeficiency diseases (SCID)
RAG-1 gene, 91, 144, 272. *See also* Recombination-activating genes (RAGs)
RAG-2 gene, 91, 144, 272
RANTES chemokine, 184
Rapamycin, 306
ras oncogene, 313
Rauscher leukemia virus, 315
Reaginic antibody, 62, 64
Rearrangement strategy, 88
Receptor activator of NF- κ B ligand (RANKL), 163
Receptor avidity, in tolerance, 197
Receptor cross-linking, 112
Receptor editing, 103, 197

- Receptors
 antigen-specific, 3
 for cytokines, 112
 innate, 2
- Recognition mechanisms, 1
- Recombinant DNA, vaccines produced by, 342
- Recombinant DNA techniques, 79
- Recombinant DNA technology, 9
- Recombinant fusion proteins, 323
- Recombinase deficiencies, 271t, 272
- Recombinases, 144
- Recombination, class switch, 94, 94–95
- Recombination-activating (RAG) genes, 91, 144
- Recombination recognition sequences, 144
- Recombination strategy, 88
- Red pulp, spleen, 29, 30
- Redness, from inflammation, 20
- Redundancy, 52
- Reed-Sternberg cells, 293
- Regulatory effects, of T cell subsets, 7
- Regulatory T cells. *See* T-regulatory cells (Treg cells)
- Reperfusion, 226
- Repertoire, 96, 100
- Reservoir of virus, 283
- Respiratory burst, 19
- Restriction fragment length polymorphism (RFLP), 303
- Reticuloendothelial system (RES), 14, 31
- Retinal pigment epithelial (RPE) cells, 201
- rev* protein, 283
- Reverse transcriptase, 283
- Rhesus incompatibility reactions, 251
- Rheumatic fever, 204, 253
- Rheumatoid arthritis (RA), 23, 177, 190, 206t, 211–212, 222, 253
- Rheumatoid factor (RF), 212
- Rhinitis, 233, 245
- Rhogam, 251, 346
- RIG-I-like receptors (RLRs), 16, 17–18
- Rituxan, 300
- Rituximab, 213, 322
- RNA transcript splicing, 89. *See also* Anti-RNA-specific B cells; Messenger RNA (mRNA); Primary RNA transcripts
- Route of administration, immunization strategy and, 38
- S. pneumoniae*, 167, 168
- S-protein (vitronectin), 224
- Salmonella typhi*, 339
- SAP molecule, 278
- Scatchard analysis, 69–70
- Schistosomes, 239
- SCID-human chimeras, 82. *See also* Severe combined immunodeficiency diseases (SCID)
- Scleroderma, 206t, 208
- Second-set rejection, 300
- Second signals, 129, 141, 153, 154, 156
- Secondary antigen response, 105
- Secondary immune response, 38
- Secondary immunodeficiencies, 269, 293
- Secondary immunodeficiency diseases, 281–282
- Secondary lymphoid follicles, 29
- Secondary lymphoid organs, 27, 27, 29, 33
- Secondary response, 62–63, 64
 incubation period and, 340
 significance of, 339
- Secreted antibodies, 47
- Secreted antibody structures, 56
- Selectins, 112, 150
- Selective binding, MHC molecules and, 118
- Self-antigens, 194, 214
 circulating, 5
 prevention of immune responses against, 9
- Self-MHC, 146, 197. *See also* Major histocompatibility complex (MHC)
- Self-MHC restriction of T-cell responses, 147
- Self-molecule-derived peptides, binding by MHC molecules, 128–129
- Self-peptides, 127
- Self-tolerance, 194
- “Semi-invariant” TCR, 172
- Sendotoxins, 23
- Sensitization phase/stage
 of allergic reactions, 234
 in delayed-type hypersensitivity, 260, 260
- Sepsis, 21
- Septic shock, bacterial, 188, 192
- Sequestered autoantigens, 194
- Seroconversion, 284
- Serological methods, 67
- Serology, 67
- Serotonin, 238
- Serum, 48
- Serum amyloid A, 22t
- Serum amyloid P component, 22t
- Serum proteins, electrophoretic mobility of, 48
- Serum sickness, 253, 255, 255, 306
- Serum therapy, 344–345, 345
- Severe combined immunodeficiency disease mice, 82
- Severe combined immunodeficiency diseases (SCID), 82, 186, 190, 270–274, 271t, 307
- Sézary syndrome, 292
- Shared epitopes, 212
- Shope papilloma virus, 315
- Sialyl Lewis moiety, 183
- Signal transducers and activators of transcription (STATs), 187, 188, 192
- Signal transduction, cytokine receptor-mediated, 186–188
- Signal transduction molecules, 102, 139, 141, 142
 membrane-immunoglobulin-associated, 111
- Signaling complexes, activation of, 157–158

Signaling lymphocyte activation molecule (SLAM), 278
“Signature” cytokines, 161
Simian immunodeficiency virus (SIV), 228, 287
Sirolimus, 306
Sjögren’s syndrome, 206t, 208, 212, 290
Skin-prick test, 242
Slow-reacting substance of anaphylaxis (SRS-A), 238
SLP76 molecule, 158
Small lymphocytic lymphoma (SLL), 290
Smallpox, 3, 8, 9
Smallpox vaccine, 338, 342
Solid-phase immunoassays, 75–76, 85
Soluble HEL (sHEL), 196. *See also* HEL (hen egg lysozyme)
Soluble TNF receptor molecules, 190. *See also* Tumor necrosis factor α (TNF- α)
Solutions, reactions in, 72
Somatic gene conversion, 96, 96
Somatic hypermutation, 95–96, 97–98, 106–107, 139
Southern blot analysis, 287
SP-40, 40 protein, 224
Specific antibody, 332
Specificity, 100
in adaptive immune response, 5
of immunoglobulins, 47
in immunologic interactions, 41, 42
Spirochetes, 332
Spleen, 29, 109
functioning of, 29
overall and section views of, 30
Splenic macrophages, 13
Splenic marginal zone B cells, 104
Splicing, RNA transcript, 89
Src family of tyrosine kinases, 157
Stage-specific markers, 110–111
Staphylococcus aureus, 188
Steady state period, in primary response, 62
Still’s disease, 212
Strep throat, 336
Streptococcus pneumoniae, 109, 334
Streptococcus pyogenes, 188
Stroma, 101
Subclasses, 50
Subcutaneous antigen administration, 38
Sugars, 19
Sunburn, 23
Superantigens, 129, 138, 160, 188, 335
Suppressor of cytokine signaling (SOCS), 187
Surrogate light chains, 102
SV40 virus, 315
Switch (S) region, 94
Syk tyrosine kinase, 273
Synergistic effects, 177
Syngeneic animals, 82
Syngeneic individuals, 299

Syngraft, 299, 299
Synovium, 211
Synthetic peptide vaccines, 343
Systemic immune complex disease, 252, 253, 255
Systemic inflammatory responses, 20–21
Systemic lupus erythematosus (SLE), 21, 76, 189, 202, 205, 206t, 208, 208–209, 209, 213, 219, 225, 252, 276, 280
T-B interaction disorders, 277–278
T-cell clones, 4
T-cell deficiencies, with normal peripheral T-cell numbers, 275
T-cell dependent antigens, 20, 27
T-cell derived cytokines, 161
T-cell development, thymic nonlymphoid cells in, 144–145
T-cell differentiation, in the thymus, 144–149
T-cell exhaustion, 159
T-cell growth factor (TCGF), 158, 176, 177
T-cell hybridomas, 80
T-cell lineages
cytokines that induce differentiation of, 181–182
role in allograft rejection, 302–303
T-cell lines, cloned, 79
T-cell malignancies, correlation of T-cell development with, 292
T-cell-mediated immunity, 7–8, 269
T-cell neoplasms, 287, 291–293
T-cell proliferation assays, 78
T-cell receptor diversity, generation of, 144
T-cell receptor gene rearrangements, 145–146
T-cell receptor (TCR) complex, 139–140, 140
T-cell receptors (TCRs), 4, 8, 26, 42, 88, 117, 137, 150, 153, 194, 262
antigen recognition by, 138
binding of antigens to, 41
genes coding for, 143–144
interaction with peptide/MHC, 155–156
valence and conformation by, 138
T-cell repertoire, generation of, 148
T-cell responses, 5
antigen triggers for, 128
MHC restriction of, 118, 147
T-cell surface, important molecules expressed on, 141–142, 142
T cells, 3, 6, 44. *See also* T lymphocytes
activation of, 20, 26, 27
adaptive immune responses and, 26
alloantigen recognition of, 301–302
 $\alpha\beta$, 148
APC and, 13
autoimmune diseases, organ damage and, 210–213
central tolerance and, 147, 195, 196
cognate, 105
effector cell assays for, 79

- T cells (*continued*)
 epitopes recognized by, 39, 39t
 $\gamma\delta$, 130, 142–143, 145–146, 172, 173
 immature, 119
 immunodeficiency disorders associated with, 274–276
 mature, 119
 naïve, 141, 142, 148
 subpopulations of, 7
 two-signal model for activation of, 153, 154
- T follicular helper (T_{FH}) cells, 107, 165, 173
 germinal center and development of, 166
- T helper-B cell cooperation, in use of conjugate vaccines, 167–168, 168
- T helper cells, 105, 165. *See also* T_H entries
- T-lymphocyte deficiency, 269t
- T lymphocytes, 38, 268. *See also* T cell entries
 antigen receptors expressed as transmembrane molecules on, 7
 biology of, 137–150
 tumor cell destruction by, 318
- T-regulatory cells (Treg cells), 7, 161, 164, 164, 164t, 165, 173, 198–200, 199, 213
 differentiation of, in the thymus, 149, 150
- TB^- SCID subgroup, 270, 271t
- TB^+ SCID subgroup, 270, 271, 271–272, 271t
- T^+B^- SCID subgroup, 270, 271, 271t, 272
- T^+B^+ SCID subgroup, 270, 272
- Tacrolimus, 158, 306
- Tap* gene product, 273
- TAPA-1, 111
- Target, 168
- Target cells, CD8+ T-cell killing of, 169–171, 170
- tat protein, 283
- T_c cells, 7
- TCR gene rearrangement, 150
- TCR structures, theoretical number of, 143
- TCR $\gamma\delta$ T cells, 130. *See also* T-cell receptors (TCRs)
 TCRA locus, 143, 143
 TCRB locus, 143, 143
 TCRD locus, 143, 143
 TCRG locus, 143, 143
- Teichoic acids, 332
- Terminal deoxynucleotidyltransferase (TdT), 95
- Terminal pathway, 222
- Testis, immune privilege of, 201
- Tetanus, 58, 334, 342
- Tetanus immune globulin (TIG), 346
- TGF- β , production by and major functions of, 180t
- T_H0 cell, 161
- T_H2 -cell dependency, of IgE antibody production, 234–235, 245
- T_H1 -cell lineage, 181. *See also* T helper cell entries
- T_H2 -cell lineage, 181
- T_H cells, subsets of, 7
- T_H1 cells, 161, 162, 164t, 165, 173
 differentiation of, 178
- T_H2 cells, 161, 162, 162, 163, 164t, 165, 173
 differentiation of, 178
- T_H9 cells, 165
- T_H17 cells, 161, 163, 163, 165, 173
- T_H2 IL-4 gene cluster, 234
- T_H17 T-cell lineage, 182
- Third signal, 161
- Thoracic duct, 29
- Thrombocytopenia, 213
- Thromboxanes, 238
- Thrombus, 21
- Thymectomized mice, 82
- Thymic aplasia, congenital, 274–275
- Thymic differentiation, key steps in, 145, 145
- Thymic involution, 144
- Thymic nonlymphoid cells, in T-cell development, 144–145
- Thymic selection, 146
- Thymocytes, 28, 28, 144, 145, 150
- Thymoma, 207
- Thymus-dependent antigens, 165, 198
- Thymus-dependent (TD) antibody synthesis, 104
- Thymus gland, 27, 27, 28, 150
 cellular organization of, 28, 145
 characteristics of $\alpha\beta$ T cells emerging from, 148–149
 differentiation of other cell types in, 149
 interdigitating cells of, 14
 T-cell differentiation in, 144–149
- Thymus-independent antigens, 105, 112
 conjugate vaccines: help for, 167–168
- Thymus-independent (TI) antibody responses, 109–110
- Thyroid-stimulating hormone (TSH), 207
- Thyroiditis, Hashimoto's, 206t, 209, 210, 290
- Tingible body macrophages, 107
- Tissue typing, laboratory tests used in, 303–304
- Titer, 70, 85
- TLR-1, 17
- TLR-2, 17
- TLR-3, 17
- TLR-4, 17
- TLR-5, 17
- TLR-6, 17
- TLR-7, 17, 205
- TLR-8, 17, 205
- TLR-9, 17, 205, 205
- TNF inhibitors, 190. *See also* Tumor necrosis factor- α
- TNF receptor-associated factors (TRAF), 185
- TNF receptors, 186
- TNF (TNFR) receptor superfamily, 185
- Tolerance
 to antigens, 37
 central, 194, 195–197, 213
 discovery of, 194
 neonatal, 194, 195

- oral, 200–201, 213
peripheral, 194, 197–200, 213
receptor avidity in, 197
Toll/interleukin-1 receptor domain-containing adaptor inducing IFN- β (TRIF), 17
Toll-like receptors (TLRs), 2, 16, 16–17, 155, 205
T1-1 antigens, 109
T1-2 antigens, 109
Toxic shock syndrome, 129, 160, 188, 192, 335
Toxins, 334
 neutralization of, 58
Toxoids, 41, 42
 as vaccines, 343
Toxoplasmosis, 336
Transcription factors, 89
Transendothelial migration, 22, 23
Transfusion reactions, 251
Transgenes, 82
 altered, 83
Transgenic mice, 82–83, 83
Transient hypogammaglobulinemia, 277
Transient neonatal hyperthyroidism, 208
Transitional B cells, 104
Transmembrane protein, prototypical gene coding for, 89
Transplantation, 298–309
 donor/recipient relationship in, 298–299
 hematopoietic stem cell, 307–308
 immunosuppressive drugs used in, 305t
 of specific organs and tissues, 299
 tissue, situations of, 299
 xenogeneic, 308–309
Transplantation antigens, 301
Transplanted organs/tissues, treatment of patients with, 190–191
Trastuzumab, 323
Trimolecular complex, 39
Trophozoite, 333
Tropism, 282
Trypanosomes, 335
Tuberculin, 263
Tuberculin-type hypersensitivity, 259, 263, 263–264, 265
Tuberculosis, 23
 vaccines against, 42
Tumor antigens, 312–315, 325
 categories of, 313–315, 314t
 oncogene-encoded, 315
Tumor cell adhesive properties, antibody-mediated loss of, 318, 325
Tumor cells
 cell-mediated responses to, 318–319, 325
 destruction by activated macrophages and neutrophils, 318–319, 325
 destruction by NK cells, NK/T cells, and cytokine-activated killer cells, 318, 325
 destruction by opsonization and phagocytosis, 318, 325
 destruction by T lymphocytes, 318
 MHC class I expression in, 127
Tumor growth factor- β (TGF- β), 200
Tumor immunity, effector mechanisms in, 316–318
Tumor immunology, 312–325
 major goals of, 312
Tumor immunoprophylaxis, 321–322
Tumor-infiltrating lymphocytes (TILs), 318
Tumor necrosis factor- α (TNF- α), 21, 177, 179, 183, 237
 production by and major functions of, 180t
Tumor necrosis factor- β (TNF- β), production by and major functions of, 180t
Tumor-specific antigens, 2
Tumor-specific monoclonal antibodies, 322
Tumor-specific transplantation antigens (TSTAs), 312
Tumor vaccines, preclinical and clinical, 319
Tumors
 B-cell responses to, 317
 effectiveness of immune response against, 320
 escape from immunologic destruction, 320t
 immunodiagnosis of, 320–321
 transplantable, 322
Two-chain peptide transporter (TAP), 126
Type I diabetes mellitus (T1DM), 206t, 211
Type I hypersensitivity reactions, 233–245
Type I interferons, 181
Type III hypersensitivity reactions, 249, 252–256
 systemic, phases in induction of, 254
Type-2 immune responses, 333
Type IV hypersensitivity reactions, 162, 259–265
 characteristics and pathophysiology of, 259–261
 mechanisms involved in, 260–261
Tyrosine-based inhibitory motif (ITIM), 159
Tyrosine kinases, 273

Urticaria, 241
Urticular reaction, 235
US Food and Drug Administration (USFDA), 42, 307

Vaccination, 3, 8–9, 338, 339t
Vaccines, 9, 322, 336, 337. *See also Immunization(s)*
 adjuvants and, 42
 cervical, 337
 conjugate, 109, 167–168, 168, 173
 DTP, 339
 hazards associated with, 341–342
 HIV, 287
 HPV, 342
 production of, 342–343
 in selected populations, 337–339
 site of administration of, 341
 used in active immunization, 338t
Vaccinia immune globulin, 347

- Vaccinia virus, 228
van der Waals forces, 6, 41, 52, 68, 84
Variable region, 122
 of immunoglobulins, 51–52
Variable (V) gene segment, 90
Variant surface glycoproteins (VSGs), 335
Varicella-zoster globulin, 346
V(D)J recombinase, 90, 91, 92, 101
V(D)J recombination, 90, 91
VDJ unit, 101
Vena cava, 29
Viral gene products, 314t
Viral infections, treatment of patients with, 190–191
Virulence, 328
Virulence factors, 334
Virus-carrier vaccines, 343
Virus-infected cells, MHC class I expression in, 127
Virus-specific CD8+ CTL, 170. *See also* Cytotoxic T lymphocytes (CTL)
Virus-specific CD8+ T cells, 168
Viruses
 immunity to, 330–331
 neutralization of, 58
 oncogenic, 315
 responses to, 226–228, 227, 230
Vitronectin, 224
VJ -VDJ combinatorial association, 95
von Willebrand factor, 22t
VpreB gene, 102
Waldenström macroglobulinemia, 291
Warm autoantibodies, 206
Western blot analysis, 286
Western blots, 73–74, 74
Weal and flare reactions, 241, 242
White pulp, spleen, 29, 30
Wiskott-Aldrich syndrome, 271t, 273–274, 307
Wiskott-Aldrich syndrome protein (WASP), 274
Women, HIV+, 285
World Health Organization (WHO), 287, 288t
Worm parasitism, protective role of IgE, 244, 244, 245, 246

X-HIGM, 278. *See also* Hyper-IgM (HIGM) syndrome
X-linked agammaglobulinemia, 103, 190, 276–277
X-linked lymphoproliferative syndrome (XLPS), 278
X-linked SCID, 271. *See also* Severe combined immunodeficiency syndrome (SCID)
Xanthine derivatives, 243t
Xenogeneic chimeric antibodies, 322
Xenogeneic transplantation, 308–309
Xenograft, 299, 299, 309

ZAP-70 deficiency, 271t
ZAP-70 mutation, 273
ZAP-70 tyrosine kinase, 158, 159
Zeta chain, 139, 140
Zeta potential, 70
Zone of antibody excess, 72, 72
Zone of antigen excess, 72, 72



